Intermittent hypoxia revisited: a promising non-pharmaceutical strategy to reduce cardio-metabolic risk factors?

Sleep Breath. 2018 Mar;22(1):267-271. doi: 10.1007/s11325-017-1459-8. Epub 2017 Feb 2.

Abstract

Purpose: The study aims to investigate the effects of moderate intermittent hypoxia (IH) on key cardio-metabolic risk factors in overweight and obese subjects.

Methods: Six subjects were exposed to 10 sessions of moderate IH over 2 weeks (based on [Formula: see text]; ~70 min per session). Measures were made of blood glucose (GLU) and lactate (La-); high (HDLc) and low-density lipoproteins (LDLc); triglycerides (TRG), systolic (SBP), and diastolic blood pressure (DBP); and cardiac autonomic indices [root mean square of successive R-R interval differences (RMSSD) and short-term fractal scaling exponent (DFAα1)].

Results: GLU decreased and La- increased following a single IH session (6.21 ± 1.62 vs. 5.32 ± 1.03 mmol L-1; p < 0.05; 1.14 ± 0.21 vs. 1.47 ± 0.22 mmol L-1), but no sustained change after 10 sessions of IH occurred (p > 0.05). Conversely, LDLc (3.00 ± 0.68 vs. 2.51 ± 0.60 mmol L-1; p < 0.05), LDLc/HDLc ratio (2.52 ± 0.66 vs. 2.26 ± 0.70 mmol L-1; p < 0.05), and SBP (118.6 ± 13.3 vs. 109.6 ± 11.3 mmHg; p < 0.05) were all significantly decreased after 10 sessions.

Conclusion: A short course of recurrent IH appears to be a safe and effective non-pharmacological method of reducing key cardiovascular risk factors associated with metabolic disorders.

Keywords: Cardio-metabolic risk factors; Moderate intermittent hypoxia; Obesity; Treatment strategy.

Publication types

  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / prevention & control
  • Female
  • Humans
  • Hypoxia / complications*
  • Hypoxia / therapy*
  • Male
  • Metabolic Diseases / etiology*
  • Metabolic Diseases / prevention & control
  • Middle Aged
  • Obesity / complications
  • Obesity / physiopathology
  • Overweight / complications
  • Overweight / physiopathology
  • Oxygen / administration & dosage
  • Oxygen / pharmacology*
  • Oxygen / therapeutic use*
  • Risk Factors
  • Single-Blind Method

Substances

  • Oxygen